Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:LTRN NASDAQ:MNPR NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.13$2.11$1.43▼$3.98$213.87M1.65160,717 shs70,818 shsLTRNLantern Pharma$4.57$3.82$2.55▼$6.12$49.36M1.6386,266 shs72,012 shsMNPRMonopar Therapeutics$35.71-0.4%$38.02$2.15▼$54.30$220.33M1.0520,682 shs17,461 shsSOPHSOPHiA GENETICS$3.47+5.8%$3.25$2.58▼$4.92$234.50M188,888 shs36,649 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-0.47%+2.90%+22.41%-36.80%LTRNLantern Pharma0.00%-8.42%+14.54%+27.30%+8.04%MNPRMonopar Therapeutics0.00%+3.06%-23.17%-3.22%+1,432.62%SOPHSOPHiA GENETICS0.00%+9.98%-6.72%+21.33%+6.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune1.661 of 5 stars3.51.00.00.01.50.80.6LTRNLantern Pharma2.9363 of 5 stars3.53.00.00.03.90.80.6MNPRMonopar Therapeutics2.8659 of 5 stars3.44.00.00.02.52.50.0SOPHSOPHiA GENETICS2.9969 of 5 stars3.55.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00463.38% UpsideLTRNLantern Pharma 3.00Buy$25.00447.05% UpsideMNPRMonopar Therapeutics 2.83Moderate Buy$60.0068.02% UpsideSOPHSOPHiA GENETICS 3.00Buy$8.00130.55% UpsideCurrent Analyst Ratings BreakdownLatest LTRN, SOPH, ACIU, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.007/7/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.006/23/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M6.89N/AN/A$1.29 per share1.65LTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ASOPHSOPHiA GENETICS$65.17M3.60N/AN/A$1.48 per share2.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.78N/AN/AN/AN/A-99.89%-81.58%11/6/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%N/ASOPHSOPHiA GENETICS-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)Latest LTRN, SOPH, ACIU, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025LTRNLantern Pharma-$0.53-$0.40+$0.13-$0.40N/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 million8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25$0.33+$0.58$0.33$17.49 million$18.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33LTRNLantern PharmaN/A3.523.52MNPRMonopar TherapeuticsN/A33.9333.93SOPHSOPHiA GENETICS0.623.393.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%LTRNLantern Pharma28.62%MNPRMonopar Therapeutics1.83%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%LTRNLantern Pharma8.50%MNPRMonopar Therapeutics20.50%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableLTRNLantern Pharma2010.80 million9.88 millionOptionableMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableSOPHSOPHiA GENETICS52067.58 million64.28 millionNot OptionableLTRN, SOPH, ACIU, and MNPR HeadlinesRecent News About These CompaniesSOPHiA GENETICS SA: Positive Earnings Call HighlightsAugust 14, 2025 | theglobeandmail.comSOPHiA GENETICS SA (NASDAQ:SOPH) Stock Holdings Increased by Federated Hermes Inc.August 9, 2025 | marketbeat.comSOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 7, 2025 | finance.yahoo.comSophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...August 7, 2025 | finance.yahoo.comSOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlookAugust 6, 2025 | msn.comSOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSOPHiA GENETICS Reports Financial Results for Mid-2025August 5, 2025 | tipranks.comSOPHiA GENETICS Reports Second Quarter 2025 ResultsAugust 5, 2025 | prnewswire.comSOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomesAugust 5, 2025 | prnewswire.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 123.8%August 5, 2025 | marketbeat.comSOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on TuesdayJuly 29, 2025 | marketbeat.comSOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025July 22, 2025 | prnewswire.comTurning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom IntegrationJuly 15, 2025 | pharmiweb.comPSophia Genetics launches podcast to decode data- and AI-driven medical innovationJune 27, 2025 | fiercepharma.comFAn end to an era: Supreme Court won't review IVF mixup rulingJune 26, 2025 | israelnationalnews.comIEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comFM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comZM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comTThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comF'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comINew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, SOPH, ACIU, and MNPR Company DescriptionsAC Immune NASDAQ:ACIU$2.13 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.10 -0.03 (-1.64%) As of 08/15/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Lantern Pharma NASDAQ:LTRN$4.57 0.00 (0.00%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$4.38 -0.20 (-4.27%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Monopar Therapeutics NASDAQ:MNPR$35.71 -0.15 (-0.42%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$35.21 -0.50 (-1.40%) As of 08/15/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.SOPHiA GENETICS NASDAQ:SOPH$3.47 +0.19 (+5.79%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.47 0.00 (0.00%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access